Beijing Health (Holdings) Limited

SEHK:2389 Stock Report

Market Cap: HK$515.0m

Beijing Health (Holdings) Past Earnings Performance

Past criteria checks 0/6

Beijing Health (Holdings) has been growing earnings at an average annual rate of 33%, while the Healthcare industry saw earnings growing at 11.2% annually. Revenues have been declining at an average rate of 4.7% per year.

Key information

33.0%

Earnings growth rate

33.0%

EPS growth rate

Healthcare Industry Growth11.3%
Revenue growth rate-4.7%
Return on equity-5.5%
Net Margin-75.4%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Here's Why We're Not Too Worried About Beijing Health (Holdings)'s (HKG:2389) Cash Burn Situation

Sep 05
Here's Why We're Not Too Worried About Beijing Health (Holdings)'s (HKG:2389) Cash Burn Situation

Beijing Health (Holdings) (HKG:2389) Is In A Good Position To Deliver On Growth Plans

Mar 01
Beijing Health (Holdings) (HKG:2389) Is In A Good Position To Deliver On Growth Plans

Companies Like Beijing Health (Holdings) (HKG:2389) Are In A Position To Invest In Growth

Sep 12
Companies Like Beijing Health (Holdings) (HKG:2389) Are In A Position To Invest In Growth

A Look At The Fair Value Of Beijing Health (Holdings) Limited (HKG:2389)

Feb 07
A Look At The Fair Value Of Beijing Health (Holdings) Limited (HKG:2389)

Health Check: How Prudently Does Beijing Health (Holdings) (HKG:2389) Use Debt?

Oct 18
Health Check: How Prudently Does Beijing Health (Holdings) (HKG:2389) Use Debt?

Is Beijing Health (Holdings) (HKG:2389) Using Debt In A Risky Way?

May 31
Is Beijing Health (Holdings) (HKG:2389) Using Debt In A Risky Way?

Is Beijing Enterprises Medical and Health Industry Group (HKG:2389) Using Too Much Debt?

Dec 15
Is Beijing Enterprises Medical and Health Industry Group (HKG:2389) Using Too Much Debt?

Revenue & Expenses Breakdown

How Beijing Health (Holdings) makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:2389 Revenue, expenses and earnings (HKD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24136-1021040
31 Mar 24138-821040
31 Dec 23140-621040
30 Sep 23147-711030
30 Jun 23153-811010
31 Mar 23160-891090
31 Dec 22166-981160
30 Sep 22191-791150
30 Jun 22216-601140
31 Mar 22210-501140
31 Dec 21204-391150
30 Sep 21184-811210
30 Jun 21164-1221270
31 Mar 21157-1541290
31 Dec 20150-1851320
30 Sep 20173-3111460
30 Jun 20196-4381610
31 Mar 20198-4301670
31 Dec 19201-4221730
30 Sep 19183-2151890
30 Jun 19165-82040
31 Mar 19172182200
31 Dec 18179432350
30 Sep 181721522410
30 Jun 181642612460
31 Mar 181472372340
31 Dec 171312142210
30 Sep 17151482090
30 Jun 17170-1181960
31 Mar 17167-932000
31 Dec 16164-682030
30 Sep 16104-872090
30 Jun 1643-1072150
31 Mar 1622-1051820
31 Dec 150-1031480
30 Sep 150-60920
30 Jun 150-16370
31 Mar 150-16250
31 Dec 140-16130
30 Jun 14-2112110
31 Mar 1411927210
31 Dec 1325942310

Quality Earnings: 2389 is currently unprofitable.

Growing Profit Margin: 2389 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 2389 is unprofitable, but has reduced losses over the past 5 years at a rate of 33% per year.

Accelerating Growth: Unable to compare 2389's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 2389 is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-16.9%).


Return on Equity

High ROE: 2389 has a negative Return on Equity (-5.53%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies